PBAC's latest decision on Oxycodone with naloxone: Recommended (2016). Considered for Treatment of moderate to severe chronic pain unresponsive to non-opioid analgesia. Specifically, chronic severe disabling pain unresponsive to non-opioid analgesics.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Adults with chronic severe disabling pain unresponsive to non-opioid analgesics, requiring the higher strengths (60 mg/30 mg and 80 mg/40 mg) for pain titration and management of opioid-induced constipation.
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
Cost-minimisation
ICER note
Not modelled — minor submission (formulation/strength extension with no new economic model)